Covid 19 Research using Clinical Trials (Home Page)
Data CollectionWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug361 | Biospecimen Collection Wiki | 0.71 |
| drug1086 | Hydroxychloroquine Wiki | 0.07 |
| drug1822 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004417 | Dyspnea NIH | 0.27 |
| D009369 | Neoplasms, NIH | 0.16 |
| D003141 | Communicable Diseases NIH | 0.06 |
| D007239 | Infection NIH | 0.04 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002098 | Respiratory distress HPO | 0.27 |
| HP:0002664 | Neoplasm HPO | 0.16 |
There are 2 clinical trials
Clinical Trials
1 An International Observational Study of Outpatients With SARS-CoV-2 Infection
The general aim of this study is to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations, special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-Cov-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.
NCT04385251 COVID COVID19 SARS-CoV 2 Dyspnea Other: Data Collection MeSH:Dyspnea
HPO:Dyspnea Respiratory distress
Primary Outcomes
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 days
Description: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 days
Secondary Outcomes
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 Days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 Days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 Days
2 NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Primary Outcomes
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 daysDescription: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 daysSecondary Outcomes
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 daysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 DaysThis study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
NCT04387656 Asymptomatic COVID-19 Infection Laboratory-Confirmed Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Symptomatic COVID-19 Infection Laboratory-Confirmed Procedure: Biospecimen Collection Other: Data Collection MeSH:Infection Communicable Diseases Laboratory Infection Neoplasms
HPO:Neoplasm
Primary Outcomes
Description: Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit [ICU] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.
Measure: Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity Time: Up to 2 years
Description: Describe the degree to which COVID-19 interrupts, delays, or otherwise alters cancer treatment for subgroups of patients defined by cancer type and/or treatment modality. Describe the association between changes in cancer therapy and clinical outcomes. Evaluate association of COVID-19 with outcome by comparison to historical controls in subgroups of at least 50 patients using log rank tests to assess time to survival event.
Measure: Effects of COVID-19 on cancer therapy and association with clinical outcomes Time: Up to 2 years
Other Outcomes
Description: Analysis will include time to development of antibodies, prevalence of cytokine abnormalities, and genome-wide association study (GWAS) to define genetic polymorphisms associated with severe COVID-19 disease/mortality.
Measure: Collection of blood specimens for future biomarker studies Time: Up to 2 years
Related HPO nodes (Using clinical trials)
HP:0002094: Dyspnea
Genes 466
RSPH1 PFN1 NKX2-1 SPAG1 ATRX PRRX1 TSC2 RPS28 SH2B3 STAT5B LGI4 DNAH1 UBE3B PON1 DPM2 PRKAR1A COL2A1 GATA6 SFTPC RRM2B PPARGC1A DNAAF1 TRAK1 LTBP3 MAPT DNAH9 FAM13A STN1 ORC6 TRPM4 HCCS RUNX2 GLA DBH DNA2 TERT RSPH4A CCR6 TNNT2 GAS8 AK9 MEGF10 SLC5A7 ACVRL1 COLQ FGFR1 HLA-B CCDC65 RUNX1 BCOR ORC6 SERPINA1 MYH11 SCO2 NDUFS2 NEK1 SETBP1 IRF2BP2 ALAS2 MYBPC3 SCN4A VPS33A GNAS OPTN COL13A1 GBA OTX2 C9ORF72 SCNN1A UNC13A CSF2RB CHRNE ACADVL COX8A SFTPC ABCG8 SFTPB MARS1 NOD2 NUMA1 COL2A1 MAPT LAMB3 FOXF1 COL13A1 ERBB4 SCN5A UBQLN2 GALC DNAAF6 SFTPA2 JPH2 KAT6A CCDC103 SQSTM1 SPP1 SOX9 SSR4 DNAAF4 PLEC FGFR2 TNNI3 NPM1 ATP11A SCNN1B EDN1 ND5 CSPP1 MUC5B NAGS MYH11 CCNF EFEMP2 MYO9A IRF5 FOXJ1 AGRN LDLR WIPF1 COX6B1 MMAA SNAP25 TSC1 CAV1 SRP54 SMAD3 COX14 DCTN1 EP300 DNAL1 NEB TREM2 CAV1 NABP1 PNKD TERC ELN PYGM SFTPC STAT4 HLA-DRB1 WAS FLNC GMNN CASR RSPH9 NEFH COA3 GATA4 SOD1 EFTUD2 TRMT5 ITGA3 MGME1 TNNC1 VCP LAMC2 TARDBP FBN1 TBL1XR1 MRPL3 TGFBR1 MYPN MYL2 CREBBP DSC2 ZFPM2 COL1A2 SLC25A1 ACADM HBB LRP4 IRAK1 SCO2 EPOR SCN1B DNAJB6 DNAI1 DPM1 BMPER DNAJB13 GAA FBP1 ETFDH PARN STX16 CHMP2B FOXP3 CFAP410 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 ND3 CPT2 SLC18A3 CHRND CDC45 NR2F2 TRNW NKX2-1 SCNN1G CDC6 TGFBR2 ND6 SLC52A3 FGFR2 MYLK LRRC6 RPS26 DNAAF5 CCNO NDUFAF3 COX20 CFTR TTN DNA2 USP9X NGLY1 XYLT1 MGME1 CYB5R3 LRRC56 EPHA4 MMUT SYT2 LAMB2 TERT PMM2 DNAAF3 SLC25A4 FLNC STT3B DPP9 CHRNA1 BMPR2 ASAH1 AIFM1 EOMES CRELD1 CYB5R3 JAK2 CBL SCO1 KLHL7 VAMP1 ALDH7A1 MCIDAS PGM1 DAO SCN4A NAGS NDUFB8 TACO1 TRNE LYRM4 PON2 SURF1 COX7B COL2A1 CFAP221 PET100 LAMA3 CHRNB1 PML PIGT RPGR STK36 EDA HNRNPA1 HLCS DSP IFT52 FBLN5 NPPA OFD1 APOB PRKCSH COL2A1 CHRNE NME8 FUS ND1 SIK1 ADNP STT3B GLE1 TGFB2 ADCY6 COX10 CFAP298 SMPD1 MATR3 CFAP300 BTNL2 PON3 SLC25A1 HLA-DRB1 RAPSN SPEF2 AIMP2 ACTA2 SCN5A ZBTB16 ZMYND10 SMAD4 COA8 GNAS PRKG1 COQ7 TRIP11 MUSK GLT8D1 ATP6 CCDC39 ARMC4 ABCA3 TRMU CYB5A PRRX1 IKZF1 GNAI3 DNAI2 ORC1 RARA NEK10 SFTPA1 ZIC3 ANXA11 POLG LIFR SLC2A10 GTPBP3 DMPK DOK7 POLG2 MYL3 RTEL1 PCSK9 TAF15 CSF2RA FGFR2 CHAT KCNJ6 FIP1L1 ISCU ASXL1 SERPING1 ETFA ATXN2 DYNC2LI1 TRNK TRNN FBP1 TBX4 TSC2 CHRNA1 COA8 SBDS SLC12A3 VPS33A SFTPA2 TWNK MMUT COPA PLCB4 STAT5B ETFB ENG TRNS1 GBA GAS2L2 PRKAR1A SCN4A FGFR2 VCP BMPER TET2 CCDC151 MFAP5 TRPV6 TBK1 NUP214 MMAB DNASE1L3 SLC35A1 CLCNKB TK2 LOX RNU4ATAC TET2 FAM20C LDLRAP1 IFT81 CHRNB1 DISC1 TGFB3 ERF FIG4 STAT3 MUC5B CHRNE EPHB4 PRPH DNAH5 GBA PUF60 BTNL2 TTC12 ORC4 TUBB4A ABCG5 ARX CRLF1 SDCCAG8 GYG1 CHCHD10 TBC1D24 ORC1 EIF2AK4 MPC1 CHRND SRSF2 CCDC40 CSF2RB ND4 ANG CHAT TSC1 VAPB NKX2-5 DNAAF3 TTC25 VCL DNAAF2 TRNK DPM2 DRC1 PRRT2 ND2 TRNE IL1RN RSPH3 DNAJC21 KIF20A USP9X HLA-DRB1 TRNV PSAP HYDIN KCNA1 CDT1 CCDC114 MAT2A ABCA3 GATA6 NDUFB11 CNTNAP1 FOXE3 CCN2 GNAS AGRN TRIP11 TET2 DNAH11 Protein Mutations 0
SNP 0
HP:0002664: Neoplasm
Genes 1515
EPCAM BAP1 CYLD WT1 CTBP1 GLI3 CTNNB1 ELMO2 ATRX TERT EDN3 MTAP TSC2 RAD51 BLNK KCNAB2 WDPCP SPINK1 ARID1B PTEN STK11 XPA PTH1R TCF4 EPCAM NF1 GPC3 ERCC3 MC1R CASP10 PDGFRA RPL5 CDH1 BRIP1 RUNX1 KRAS SFTPC GPR35 MYLK STS DYNC2LI1 RAG2 CBL FOXE1 STAT3 TTC37 ABL1 NSD1 ATM KCNH1 GPR101 IGH KRT17 SUFU TERT KRAS GPC3 CYP11B2 MLH3 PTCH1 FAH MSH2 EXT1 CCND1 MSH3 ATP7A SEC23A PHOX2B HAX1 MYD88 LMO1 PIK3CA PRLR AXIN1 TCF4 RUNX1 AKT1 ERBB2 REST DCLRE1C SERPINA1 ERCC3 TMC6 RASA1 MSH3 TRNL1 CALR HRAS INS RNF113A SETBP1 CDH1 SLC37A4 TFAP2A CDH1 PTCH1 KIT PTEN IL1RN MLH3 MUTYH PTEN KIT GBA BCL2 KCNH1 GINS1 ESCO2 TET2 SLX4 DICER1 PALB2 NEK1 ESCO2 COL7A1 PTCH2 WT1 WRN GCM2 BRD4 BRAF TREX1 THPO SUFU NRAS CDC73 POU6F2 GNAS DAXX BUB3 RSPO1 MNX1 ERCC2 RPS28 ANTXR2 CTNNB1 POT1 FANCA KDM6B RET MST1 NOTCH3 FGFR1 KRAS LYST CHIC2 TMC6 MET KRT10 UROD SLC25A11 ARSA EVC2 TEK XRCC2 CASP8 ASCL1 IL1B TERF2IP DICER1 MPL OFD1 RHBDF2 DICER1 MDM2 WT1 MMP1 CDKN2A FGF8 NR4A3 FGFR2 OCRL TP53 ERCC2 SUFU ERCC4 ALX4 TINF2 DCLRE1C SRY SRP72 NF2 GNAS LETM1 TP53 FANCB TAL1 TDGF1 BRCA1 LEMD3 NF2 BRAF NUP214 RAD21 COL18A1 SDHD ICOS CEP57 BAP1 FANCM PTPRJ FANCE SLC22A18 PIK3R1 JAK2 FLT4 SMO WIPF1 DLST NF2 RAD50 MEN1 CHEK2 GPC4 WDPCP CYP2A6 HBB GANAB XRCC4 TET2 ATP7B EP300 DIS3L2 HFE CARD14 OFD1 ALX3 VANGL1 BAP1 SDHB EXTL3 PIK3CA GATA2 ALX3 BCL10 KIT WAS FGFR2 RMRP TWIST1 BMPR1B DIS3L2 ERCC3 FOXP1 SMAD4 CALR APC PCGF2 USP8 DMPK NRAS DKC1 BRCA1 ADAR BCR RSPO1 SLC45A2 GJC2 TNFRSF4 AKT1 IFIH1 MSH6 DICER1 PAX6 TGFBR2 SRY KLHDC8B CPLX1 MSH6 AIP PMS1 CREBBP ERCC2 CTSA APC MMP1 SH2B3 PKD1 TRNF SEC23B DNAJC21 STK11 BCR HBB MITF IGLL1 ALX4 MDH2 AKT1 SCN4A SDHAF2 PRKN PLA2G2A RNF43 DNMT3A TERT NSD2 RMRP FANCG BRCA2 CAT TP53 BMPR1A MAD2L2 SIX6 DDB2 GREM1 KRT17 PAX4 RPS17 TRPV3 ERCC4 C11ORF95 APC IL12RB1 BRIP1 PPM1D SDHB NODAL HNF1A FLT4 MSH6 ERCC6 BTK SLC26A4 SEMA3C AR NEK1 TERC RPL35A RPS20 CDKN1C SF3B1 TERC PTEN RFWD3 BRCA2 KCNQ1OT1 RPL10 ACTG2 MAGT1 ALK BLM H19 LEMD3 RPL31 MLLT10 PYGL RPL15 IRF1 CR2 MITF PTEN MYC PTPN11 TUBB TCF4 KCNQ1 NFKB2 ALX1 HLA-DRB1 APC EWSR1 NBN CDKN2A ERCC4 GCK DLL1 SLC25A11 PDGFB L2HGDH PRKCD CTC1 PIK3CA SUFU RPL27 KIF1B SRC CIB1 RECQL4 CDKN2B MSH3 BRCA2 PALB2 PDE6D SDHC SDHD CCL2 CHEK2 PMVK XPC STK11 PIK3CA MVD DHCR7 KIT GPC6 KARS1 MNX1 VHL TUBB NAB2 KEAP1 TSC1 NQO2 APC SDHB VHL TCTN3 RECQL4 PMS2 RAD51C STAG3 SNAI2 MAP3K8 SETBP1 SDHB NPM1 RAD51C RARA ERBB2 ERCC5 ATRX CHEK2 KRAS BRCA1 TFAP2A SLCO2A1 PHOX2B PTEN COL2A1 PIGL PDGFRA APC CPLANE1 AURKA SDHD LAMA3 VHL RPS26 GFI1B CDKN1B PRDM16 AXIN2 FZD2 AP2S1 LZTR1 TP53 TP53 GNA14 CTNNB1 MSTO1 PIK3CA RPS29 CALR DHX37 MYF6 SDHC MALT1 ELANE SDHD SLC26A4 MAP3K1 GDNF MSH2 SDHC TGFBR1 RUNX1 CREB1 CDKN2A TSC2 KRAS TNFRSF10B LMNA WWOX PHOX2B EDN3 RPS10 RSPRY1 TRIM37 RET MEN1 BCL10 MSH2 TNFRSF13C FOXE1 FANCC H19-ICR BLM ERCC6 LIG4 BDNF LMOD1 NF2 TMEM107 CYLD GJB2 EXT1 CTSC PHOX2B RAD51D RASGRP1 RB1 TGFBR2 SRY MYH8 KRAS TINF2 RECQL4 H19 PRF1 GDNF MXI1 SMPD1 WT1 HRAS COL1A1 PDGFRB FAS FANCD2 NF1 DISP1 PDGFRL IKBKG BIN1 BRCA2 ADA POLE AXIN2 SEMA4A KRAS NRAS PALB2 CHEK2 ASCL1 POLE TLR2 PIK3CA MINPP1 SOS1 CYLD CTLA4 POT1 ASXL1 CDC73 APC SAMD9L WT1 TRAF7 GATA4 PIK3CA DYNC2LI1 ATP7A CBFB MST1R GCGR MPL COL4A5 SMAD4 CDKN1A SDHD TRIM28 POLH GPR101 PIK3CA FLCN GPR143 RB1 SBDS SLC12A3 KLF6 ICOS GNB1 PIGA TYROBP GFI1 RAD51 SLC26A2 MC1R TREM2 SFTPA2 JAG1 BAP1 EGFR IGH KIT PLCB4 NLRP1 HNF1B ZFHX3 EPHB2 KLLN OCA2 WT1 FAH FH TERT SRD5A3 LIG4 NFKB1 RNF43 KIT STAT1 IFNG BMPR1A ERCC3 TBX18 TET2 MAP2K1 EXT2 HRAS RTEL1 FGFR3 PTEN CTNNB1 MAP2K2 MEN1 APC CLCNKB AKT1 ESCO2 CDC73 MS4A1 BRAF CRKL NUTM1 CDK4 NTHL1 ETV6 TET2 SQSTM1 FAM20C PIGL SEC23A ATM PALB2 TYR SRSF2 EXT2 GJB2 DNMT3A HRAS TCOF1 CHEK2 CDH1 FH DKC1 POLE PIK3CA PTCH2 AKT1 PAX3 FH ADAMTS3 APC PMS1 RAD51C PLCD1 PUF60 DIS3L2 CDH23 SCN9A FOXC2 SMARCB1 CDKN2A VANGL2 ENG SH2D1A SDHB SOX9 BRAF SDHA PGM3 ERCC2 GJB2 TBC1D24 CHD7 MPL DHH PTCH1 CALR IL12A TNFRSF13B CD28 MLH1 PTPN12 OFD1 MLH3 REST CCDC22 APPL1 COL14A1 IGH PSENEN IL2RG MC1R SMARCA4 CYLD KIF11 PHKG2 JAK2 COL2A1 AXIN2 FLNA WNT5A TYR EP300 GLI3 EXT2 MGAT2 KCNE3 ECE1 PARN IDH2 TSC1 ARL6IP6 FGFR3 SMAD4 HMBS SLC6A17 PRKAR1A BAP1 KDSR DHCR24 CXCR4 DDX41 GABRD RET NR0B1 DMRT3 CCND1 GDF5 POU6F2 CTLA4 TBXT FANCA NRTN PHKA2 KIT ITK RNASEH2A PERP CDC73 OFD1 CYP2D6 RET MEN1 CD27 PARN FUZ RPS19 MSH2 SMARCE1 TNFSF12 ZSWIM6 TERT RHOH NF1 BUB1B SLX4 LIG4 PDGFRL TNFSF15 OPCML APC PRKCD SETD2 RPS19 BRCA1 FAT4 ANTXR1 WNT10A SUFU TP63 EFL1 IL7 MN1 DOCK8 CDC73 SSX1 TMEM231 MPLKIP VHL MINPP1 BIRC3 PDX1 STS PSAP HNF1A JAK2 FANCL POT1 GNAS TERT CD79A KLF11 WRN MAPRE2 LIG4 CYSLTR2 DNM2 SH3GL1 KIT FOXH1 RELA KRAS PRKAR1A ERBB3 FGFR2 H19 TJP2 CD81 PNP MSH6 WT1 THPO ATP6V1B2 GNAQ BRCA1 WRAP53 ERCC3 CHRNG KRT14 TSC1 DLC1 CTNNB1 FGFRL1 SDHC GDNF HABP2 NRAS ATR TRNK BMPR1A TERT BRAF AKT1 XPC FGFR3 NUP214 TRIP13 SMARCD2 ZSWIM6 PIEZO2 EVC IL6 HRAS GPC4 TNFRSF13B PALLD CDKN2A POLR1D TP53 FOXO1 BRCA2 FIBP CDH23 RB1CC1 B3GALT6 FLT3 GJA1 SH2B3 MRAP MTOR AR FOXI1 TP53 GNAQ KRT6B MYD88 KRT16 TP53 NF1 MYSM1 MGMT KIT NF1 GPC4 GCM2 SIX3 PIK3CA RAD21 HRAS PMS2 ASCC1 BRCA2 GAS1 FASLG SDHD NRAS C2CD3 KDR SDHA SMAD4 SOX2 NBEAL2 SRGAP1 AGGF1 ATM AKT1 RPGRIP1L NOD2 BAX BRCA2 H19-ICR TGIF1 MAPK1 ESR1 EXT1 RPL11 KRAS BCL10 SKI LAMB3 XIAP SDHC HABP2 TRNS1 CCM2 FIBP PIK3CA TRIM28 HRAS SCN10A NF1 WT1 CPLANE1 HFE F5 C2CD3 GNPTAB TBX2 KLF6 GATA2 VEGFC RNASEH2B CBL SEMA3D ARMC5 CXCR4 JAK2 IGF2 FGFR2 NRAS UBE2T ARHGAP26 SCN11A MEN1 LMX1B F13A1 BCR COMP EDN1 SDHC ACTB GDNF CDKN2C ASPSCR1 NAGS PDGFRB PALB2 DLEC1 BCL10 STAR GNA11 PORCN RNR1 FLCN SPIB WT1 RET SDHB SLC22A18 ERCC4 CDKN2A CTHRC1 DLST OGG1 POLD1 DCC IL2RG REST SRP54 RAF1 TSC1 SRP54 IDH1 ACD KIT ACAN NSD2 TOP2A CASP10 DVL1 PTPN11 CASP10 STIM1 KRT9 AR CIB1 GNAS AR VAMP7 MRE11 GFI1 RPS14 BCL10 CACNA1S TP53 VANGL1 SKIV2L PTCH2 G6PC LRP5 PDGFRB BARD1 RPS27 RPS7 GNAS ENPP1 STAT6 ACVR1 MTM1 NEUROD1 TNFRSF13C PKD2 RUNX1 STK11 FGF3 TRIP13 SIX1 BRCA2 LAMC2 NELFA DVL3 GJB4 NSUN2 CDKN1B CTNNB1 POLR1C GJB3 SMARCB1 SBDS LMNA KRAS TRNH ECM1 STK4 ANTXR2 SOS1 BAP1 MSX2 DICER1 SDHB ACD WRAP53 BRCA1 ATP7A BUB1B RYR1 RET BRCA2 TP53 DPM1 BRCA2 BCR POLD1 TCIRG1 PTPN11 HOXD13 CR2 TARS1 JAK2 BMP2 MUTYH FLT3 TRNS2 MTMR14 NR5A1 ABCA5 RET AHCY TSC2 KIT KCNQ1OT1 RNF6 RAD54L HNF1A HMMR RNF139 WWOX TCTN3 BRAF FCN3 RNASEH2C AIP PRKN SF3B1 MSH6 NSD1 PTCH2 CCBE1 RECQL4 PMS2 ERCC2 HNF4A MMEL1 BUB1 TET2 TRPS1 ABCC6 RET IRF5 CDKN2B PDGFB USP9X TAL2 INTU GNAS HDAC4 MFN2 DYNC2H1 PIK3CA PLAG1 ATM MAX FAS PIK3CA CYP11B1 CCND1 H19-ICR PTCH1 MUTYH ABL1 ODC1 FGFR2 COL7A1 MSR1 BRCA1 RB1 TNFRSF1B COL7A1 FLT4 GPC3 TGFBR2 ATRX RAG1 PRCC BRAF TNFRSF1B FANCE RAD54L CBL SDHB TERT SDHD RPS24 FASLG MET KRT17 GATA1 ERBB2 FGFR1 KAT6B ABCA5 SDHAF2 SLC25A13 NOP10 GATA2 RFWD3 PDGFRA SPRTN MLH1 NKX2-1 IGF2R CD19 MAP3K1 TREX1 TRNP ZFPM2 CTNNB1 TRNQ WWOX IGHM MYH11 TMEM127 CDON NF2 SAMD9 PTEN RNASEL IDH2 HNF4A GTF2H5 GLI3 HRAS LPP DDB2 KIT PIK3CA PDCD10 HSPG2 HFE RPL26 BRIP1 ASXL1 SDHD CEBPA ACVRL1 NRAS CD19 GNAQ TET2 TCTN3 SMARCB1 FLCN ABCB11 BLK RAD54B SDHC FH AKT1 ANTXR1 FANCF HNF1B EXOC6B SAMHD1 SHOX MYO1H COL11A2 KCNJ10 TRIP13 CC2D2A LZTS1 SEC23B GPR101 DOCK8 BRCA2 NBN SLC26A2 SPRED1 VHL KRT1 LIN28B GTF2E2 NRAS ZIC2 SNAI2 SH3KBP1 SHOX BCL6 NTHL1 RHBDF2 CD28 MCM4 CCND1 FANCG SMARCAD1 GATA2 RERE YY1 ASXL1 IL7R TMEM67 C1S TAF1 FGFR3 NBN KRAS KIF1B AIP KCNJ11 LETM1 FANCI MLH1 MBTPS2 NRAS NEK9 GNAI3 APC2 EYA1 ZAP70 EXT2 BUB1 SSX2 LIG4 CARMIL2 SLC17A9 TMC8 PCNA EPAS1 TFE3 BRCA2 DHH MAP2K1 CASP8 CDK4 PDGFB RTEL1 EWSR1 PTEN VHL GJB6 NDP RNF6 TNPO3 TGFBR2 TXNRD2 PNP TAF15 TRNK SMO NOTCH1 LRRC8A RASA1 TSC2 ABCC8 PRKAR1A BAX IDH1 SLC22A18 ADA FAN1 TG PTEN BMPR1A MSTO1 ERCC5 IRF1 MLH1 NRAS MLH1 PICALM FANCD2 SF3B1 BICC1 RPS15A TERT KLLN ELANE FAM149B1 GATA1 SASH1 INPP5E TP53 WT1 BMPR1A PTPN11 PTPN11 MYCN XPA EDNRB TP53 FLI1 GDF2 PHB BMPER FGFR3 PTEN MCC EXT1 MC2R KCNN3 DNASE1L3 DHCR7 RASGRP1 SHH NPM1 SLC26A2 SLC37A4 IGF2 RPL18 SH2B3 PTCH1 BRAF PAX7 INHBA BMPR1A KIF7 XRCC3 IGF2 POU2AF1 DNAJC21 CYP26C1 RB1 MPL REST KIAA0753 DNMT3A ERCC6 MUC5B MLH3 ASXL1 MPL NOTCH3 KCNJ10 SMARCE1 TSR2 RPL10 KRT1 SLC25A13 WT1 NNT TP53 GNA11 GLI1 BARD1 FLCN COL7A1 SRP54 GLI2 EDN3 PTPN3 WT1 TMEM127 CD79B GATA2 TERC FN1 EIF2AK4 RAD51 WASHC5 SAMD9L AIP TP53 AAGAB RB1 TP53 KRT5 ADA2 HSPA9 PIK3CA SRSF2 PHF21A IDH1 KRAS KRAS CHEK2 BUB1B RET FANCC TP53 WHCR RAD54B NUMA1 SDHB HMBS TMEM216 SMAD4 MAFA MSH2 RPL35 CDKN1B IGF2 PPP2R1B CD70 CEL MAD1L1 MAX ALK GPC3 FERMT1 KIF1B TCF3 POLH PIK3R1 USF3 FDPS MYC DNAJC21 TNFSF12 HACE1 CDH1 SDHA ND5 NHP2 PIK3CA RPS14 NBN WNT10A ING1 CASR SUFU FGFR3 HPGD BTK ENG DCC CASP8 PHOX2B STAC3 USB1 KRIT1 PHOX2B TET2 SMAD4 JAK2 BCHE APC MVK SMAD7 SMO DKC1 SMARCB1 VHL F13B TINF2 USP8 FGFR1 FOXI1 TET2 CD96 TET2 JAK2 KRAS Protein Mutations 75
C10D C377T C677T C797S D816V D835V D842V E10A E17K E542K E545K F1174L F31I G12C G12D G12V G13D G156A G20210A G719A G719C H1047R H1112L H1112Y H1124D K652E L1213V L265P L858R L861Q M1149T M1268T P1009S P13K P1446A P286R P4503A Q12H Q21D R132C R132G R132H R132L R132S R132V R140L R140Q R140W R172G R172K R172M R172S R172W R988C T1010I T1191I T315I T790M V1110L V1206L V1238I V411L V57I V600D V600E V600K V600M V600R V617F V941L Y1248C Y1248D Y1248H Y1253D Y842C HP:0002098: Respiratory distress
Genes 233
RSPH1 NKX2-1 SCO1 SPAG1 KLHL7 VAMP1 ALDH7A1 PRRX1 TSC2 MCIDAS RPS28 NAGS NDUFB8 LGI4 DNAH1 TACO1 TRNE LYRM4 UBE3B DPM2 SURF1 COL2A1 COX7B COL2A1 CFAP221 PET100 DNAAF1 TRAK1 RPGR STK36 EDA MAPT HLCS DNAH9 ORC6 HCCS RUNX2 IFT52 FBLN5 OFD1 RSPH4A COL2A1 CHRNE NME8 GAS8 MEGF10 SLC5A7 ND1 SIK1 ADNP STT3B COLQ ADCY6 COX10 FGFR1 CCDC65 CFAP298 CFAP300 SCO2 NDUFS2 SETBP1 SPEF2 AIMP2 VPS33A COL13A1 ZMYND10 COA8 OTX2 COQ7 TRIP11 CSF2RB ACADVL ATP6 COX8A CCDC39 ARMC4 TRMU SFTPB PRRX1 GNAI3 DNAI2 ORC1 COL2A1 NEK10 ZIC3 LIFR MAPT SLC2A10 DMPK FOXF1 GALC DNAAF6 CSF2RA FGFR2 CHAT KAT6A CCDC103 SERPING1 ETFA SOX9 SSR4 DNAAF4 FGFR2 DYNC2LI1 TRNN FBP1 EDN1 ND5 SBDS SLC12A3 NAGS EFEMP2 VPS33A MYO9A MMUT COPA PLCB4 STAT5B FOXJ1 AGRN ETFB COX6B1 MMAA SNAP25 TRNS1 GBA GAS2L2 SRP54 FGFR2 BMPER COX14 CCDC151 TRPV6 EP300 NUP214 DNAL1 MMAB SLC35A1 CLCNKB TK2 SFTPC FAM20C IFT81 GMNN RSPH9 COA3 DISC1 EFTUD2 ERF ITGA3 EPHB4 DNAH5 GBA PUF60 TTC12 CREBBP ORC4 TUBB4A ZFPM2 SDCCAG8 SLC25A1 TBC1D24 SCO2 ORC1 MPC1 DNAI1 DPM1 BMPER DNAJB13 CCDC40 ETFDH ND4 CHAT TSC1 FOXP3 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 DNAAF3 TTC25 ND3 DNAAF2 CPT2 SLC18A3 TRNK CDC45 DPM2 TRNW NKX2-1 CDC6 DRC1 ND6 SLC52A3 ND2 FGFR2 TRNE IL1RN RSPH3 LRRC6 RPS26 DNAJC21 DNAAF5 CCNO NDUFAF3 COX20 USP9X USP9X TRNV PSAP HYDIN NGLY1 XYLT1 KCNA1 CDT1 CCDC114 LRRC56 ABCA3 GATA6 NDUFB11 MMUT SYT2 LAMB2 PMM2 CNTNAP1 DNAAF3 STT3B TRIP11 ASAH1 AIFM1 EOMES DNAH11 Protein Mutations 1
A118G SNP 1
rs7103572
Primary Outcomes
Description: Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit [ICU] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.
Measure: Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity Time: Up to 2 yearsDescription: Describe the degree to which COVID-19 interrupts, delays, or otherwise alters cancer treatment for subgroups of patients defined by cancer type and/or treatment modality. Describe the association between changes in cancer therapy and clinical outcomes. Evaluate association of COVID-19 with outcome by comparison to historical controls in subgroups of at least 50 patients using log rank tests to assess time to survival event.
Measure: Effects of COVID-19 on cancer therapy and association with clinical outcomes Time: Up to 2 yearsOther Outcomes
Description: Analysis will include time to development of antibodies, prevalence of cytokine abnormalities, and genome-wide association study (GWAS) to define genetic polymorphisms associated with severe COVID-19 disease/mortality.
Measure: Collection of blood specimens for future biomarker studies Time: Up to 2 years